Luminex Corporation Hosts Planet xMAP Europe Technology Symposium October 3-4, 2006
AUSTIN, Texas and OOSTERHOUT, Netherlands, Sept. 28 /PRNewswire/ -- Luminex(R) Corporation , a leading multiplex bioassay solutions provider, will be conducting the fourth annual Planet xMAP Europe scientific and technology symposium (formerly xSAMPLES) in Amsterdam, The Netherlands, October 3-4, at the Berlage's Exchange. The Planet xMAP Europe symposium includes presentations and workshops utilizing Luminex's industry leading xMAP(R) technology in clinical diagnostics and life sciences research. More than 350 attendees are expected to attend.
Paul C. Ladestein, Director, European Operations, Luminex Europe, stated, "Planet xMAP Europe promises to be another exceptional opportunity for end- users and potential users of xMAP(R) technology to learn first hand about the latest multiplexing innovations from renowned international scientists and Luminex Corporation thought-leaders. Designed as a symposium of best practices and innovative scientific applications of xMAP technology, it is a learning conference for both Luminex and attendees with collaboration and networking among presenters and participants."
In addition to a roster of presenters of international reputation, the Planet xMAP Europe Technology Symposium will feature a Special Session on microRNAs on Wednesday, October 4th, 12:00 noon - 2:00 pm. The recent announcement of a development and commercialization agreement between Exiqon A.S., Denmark and Luminex Corporation, USA, will be one of the topics of the Special Session.
European guest speakers include Sarah Baatout, MSc, PhD, Laboratory of Radiobiology and Microbiology, Belgian Nuclear Research Center, Belgium; Dr. Pankaj K. Bhavsar, Thoracic Medicine, Imperial College London, UK; Dr. Nicolas Orsi, Perinatal Research Group, Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, UK; Dr. Peter Nielsen, Senior Principal Scientist, Exiqon A/S, Denmark; Dr. Jochen Schwenk, Scientist, KTH - Royal Institute of Technology, AlbaNova University Center, Sweden; Professor Kai Zacharowski, MD, PhD, University Hospital, Bristol, UK; Dr. Christine S. Falk , Group Leader of the Immunomonitoring Unit at the National Center for Tumor Diseases (NCT), University Heidelberg Oncology Department, Germany; and Florence Sjogren, PhD, Manager, Core Facility/Flow Cytometry Unit, Department of Dermatology, University Hospital in Linkoping and the Clinical Experiment Research Unit at Linkopings University, Sweden.
Speakers from the USA are Patrick J. Balthrop, President and CEO, Luminex Corporation; Karen Ebsworth, Director, Microbiology/Virology and Molecular Diagnostics, Amgen; Jan Groen, PhD, Scientific Director, Focus Diagnostics Inc.; Christine Ginocchio, PhD, Director, Microbiology/Virology and Molecular Diagnostics, LIJ Health System Laboratories; Kenneth A. Pass, PhD, Chief, Laboratory of Newborn Screening and Genetic Services, Director of the New York State Newborn Screening Program, New York State Department of Health; and Dr. John C. Carrano, Vice President, Research and Development, Luminex Corporation.
These pre-eminent experts from seven countries will address the symposium on state-of-the-science topics including genomics, proteomics, drug target validation, miRNA and molecular diagnostics.
The Planet xMAP Technology Symposium topics demonstrate the utility of Luminex's xMAP technology to provide a versatile and cost-effective multiplexing approach to a wide variety of applications across the broad spectrum of clinical diagnostics, drug discovery and development and the life sciences.
Planet xMAP Europe Sponsors include the following Luminex strategic partners: Bio-Rad, Biosource, Millipore, Focus Diagnostics, Marligen Biosciences, Panomics, Rules Based Medicine, Tm Bioscience, Indicia, MiraiBio, PerkinElmer, Qiagen, R&D Systems and Zeus Scientific.
Planet xMAP Europe features a dynamic program of industry leaders and well-known scientists, workshops, discussion groups and networking events. For additional information regarding the Planet xMAP Europe Symposium or to register online, please visit http://www.planetxmap.com/ or email Paul Ladestein at firstname.lastname@example.org.
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Luminex's xMAP technology received the 2005 Clinical Diagnostics Technology of the Year Award from Frost & Sullivan. The Company was named in the 2005 Deloitte Fast 500 of fastest growing technology companies. Further information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com.
Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, Luminex's ability to scale manufacturing operations, potential shortages of components, competition, the timing of regulatory approvals and any modification of the Company's operating plan in response to its ongoing evaluation of its business, as well as the risks discussed under the heading "Risk Factors" in Luminex's Annual Report on Form 10-K for the year ended December 31, 2005, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Luminex Europe Contact: Paul C. Ladestein Director, European Operations Luminex Europe +31-162-408333 email@example.com Luminex Corporate Contact: Harriss T. Currie Vice President, Finance/Chief Financial Officer USA 512.219.8020 firstname.lastname@example.org Luminex Media Contact: Sandra Oak Nsight Public Relations USA 321.591.1509 email@example.comLuminex Corporation
CONTACT: Europe, Paul C. Ladestein, Director, European Operations ofLuminex Europe, +31-162-408333, or firstname.lastname@example.org; or Corporate,Harriss T. Currie, Vice President, Finance - Chief Financial Officer ofLuminex Corporation, +1-512-219-8020, or email@example.com; or Media,Sandra Oak of Nsight Public Relations, +1-321-591-1509, firstname.lastname@example.org, for Luminex Corporation